Sign up Australia
Proactive Investors - Run By Investors For Investors

Novogen on track to commence phase II trial of brain cancer therapy

GBM brain cancer affects 130,000 annually with 3-5% survival rate.
Novogen on track to commence phase II trial of brain cancer therapy
Phase II study to commence in 2H 2017

Novogen (ASX:NRT, NASDAQ:NVGN) is on track to commence the phase II human trial of its GDC-0084 brain cancer therapy in calendar year 2017.

GDC-0084 is an orally-administered therapy which is under development as a treatment for glioblastoma multiforme (GBM), the most common and most aggressive form of brain cancer.

GBM affects circa 130,000 patients worldwide annually, and has one of the poorest outcomes of any cancer, with only 3-5% of patients alive five years after diagnosis.

The GDC-0084 therapy is designed to inhibit tumour growth by targeting an important biochemical control mechanism that is thought to be critical to the growth of the tumour.

GDC-0084 was licensed by Novogen from Genentech, a member of the Roche Group, in October 2016.

Since the transaction, Novogen has completed the transfer of the FDA Investigational New Drug (IND) application from Genentech to Novogen.

Novogen has also taken possession of around 48.8 kilograms of premanufactured drug substance that had been prepared by Genentech in anticipation of a phase II study.

This material is now being formulated into oral capsules for use in the phase II clinical trial.

The study will be a randomized, two-arm study with 200 patients receiving either GDC-0084 or temozolomide as maintenance therapy after completion of standard radiotherapy treatment.

The primary endpoint of the study will be progression-free survival (PFS), with patients followed for overall survival.

PFS can be considered an acceptable endpoint for approval of oncology drugs by FDA.

Novogen anticipates that the phase II study will commence in the second half of calendar 2017, and will take circa 18 months to reach full recruitment, with PFS data available 12 months thereafter.

View full NRT profile View Profile

Novogen Ltd Timeline

Newswire
August 05 2015

Related Articles

scientist in a lab
September 28 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use